BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22527883)

  • 1. Conserved anchorless surface proteins as group A streptococcal vaccine candidates.
    Henningham A; Chiarot E; Gillen CM; Cole JN; Rohde M; Fulde M; Ramachandran V; Cork AJ; Hartas J; Magor G; Djordjevic SP; Cordwell SJ; Kobe B; Sriprakash KS; Nizet V; Chhatwal GS; Margarit IY; Batzloff MR; Walker MJ
    J Mol Med (Berl); 2012 Oct; 90(10):1197-207. PubMed ID: 22527883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-informed design of an enzymatically inactive vaccine component for group A Streptococcus.
    Henningham A; Ericsson DJ; Langer K; Casey LW; Jovcevski B; Chhatwal GS; Aquilina JA; Batzloff MR; Kobe B; Walker MJ
    mBio; 2013 Aug; 4(4):. PubMed ID: 23919999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group a streptococcal vaccine candidates: potential for the development of a human vaccine.
    Henningham A; Gillen CM; Walker MJ
    Curr Top Microbiol Immunol; 2013; 368():207-42. PubMed ID: 23250780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sortase A induces Th17-mediated and antibody-independent immunity to heterologous serotypes of group A streptococci.
    Fan X; Wang X; Li N; Cui H; Hou B; Gao B; Cleary PP; Wang B
    PLoS One; 2014; 9(9):e107638. PubMed ID: 25232948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infection.
    Kuo CF; Tsao N; Hsieh IC; Lin YS; Wu JJ; Hung YT
    PLoS One; 2017; 12(3):e0174464. PubMed ID: 28355251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.
    Rivera-Hernandez T; Pandey M; Henningham A; Cole J; Choudhury B; Cork AJ; Gillen CM; Ghaffar KA; West NP; Silvestri G; Good MF; Moyle PM; Toth I; Nizet V; Batzloff MR; Walker MJ
    mBio; 2016 Jun; 7(3):. PubMed ID: 27302756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.
    Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B
    mBio; 2019 Nov; 10(6):. PubMed ID: 31772056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-serotype protection against group A Streptococcal infections induced by immunization with SPy_2191.
    Sanduja P; Gupta M; Somani VK; Yadav V; Dua M; Hanski E; Sharma A; Bhatnagar R; Johri AK
    Nat Commun; 2020 Jul; 11(1):3545. PubMed ID: 32669564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.
    Caro-Aguilar I; Ottinger E; Hepler RW; Nahas DD; Wu C; Good MF; Batzloff M; Joyce JG; Heinrichs JH; Skinner JM
    Hum Vaccin Immunother; 2013 Mar; 9(3):488-96. PubMed ID: 23249976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model.
    Ma C; Liu Z; Li W; Qian X; Zhang S; Gao X; Jiang S; Wei L
    Microbes Infect; 2014 May; 16(5):409-18. PubMed ID: 24704476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active and passive immunizations with the streptococcal esterase Sse protect mice against subcutaneous infection with group A streptococci.
    Liu M; Zhu H; Zhang J; Lei B
    Infect Immun; 2007 Jul; 75(7):3651-7. PubMed ID: 17502395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.
    Pandey M; Powell J; Calcutt A; Zaman M; Phillips ZN; Ho MF; Batzloff MR; Good MF
    Sci Rep; 2017 Oct; 7(1):13786. PubMed ID: 29062085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine.
    Fritzer A; Senn BM; Minh DB; Hanner M; Gelbmann D; Noiges B; Henics T; Schulze K; Guzman CA; Goodacre J; von Gabain A; Nagy E; Meinke AL
    Infect Immun; 2010 Sep; 78(9):4051-67. PubMed ID: 20624906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
    Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
    Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice.
    Okamoto S; Tamura Y; Terao Y; Hamada S; Kawabata S
    Vaccine; 2005 Sep; 23(40):4852-9. PubMed ID: 15990202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
    J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine.
    García PC; Paillavil BA; Scioscia N; Dale JB; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM; Wozniak A
    Microbiol Immunol; 2018 Nov; 62(11):711-719. PubMed ID: 30357922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicted Coverage and Immuno-Safety of a Recombinant C-Repeat Region Based Streptococcus pyogenes Vaccine Candidate.
    McNeilly C; Cosh S; Vu T; Nichols J; Henningham A; Hofmann A; Fane A; Smeesters PR; Rush CM; Hafner LM; Ketheesan N; Sriprakash KS; McMillan DJ
    PLoS One; 2016; 11(6):e0156639. PubMed ID: 27310707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and assessment of new vaccine candidates for group A streptococcal infections.
    McMillan DJ; Batzloff MR; Browning CL; Davies MR; Good MF; Sriprakash KS; Janulczyk R; Rasmussen M
    Vaccine; 2004 Jul; 22(21-22):2783-90. PubMed ID: 15246612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Experimental Group A
    Rivera-Hernandez T; Carnathan DG; Jones S; Cork AJ; Davies MR; Moyle PM; Toth I; Batzloff MR; McCarthy J; Nizet V; Goldblatt D; Silvestri G; Walker MJ
    mBio; 2019 Apr; 10(2):. PubMed ID: 31040243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.